Swedish Study Finds Attention-Deficit/Hyperactivity Disorder (ADHD) Medications Linked With Safer Outcomes
Dr. Ryan Sultan - Director of Integrative Psychiatry and a Columbia University Psychiatry Assistant Professor and internationally recognized ADHD expert – authored an invited commentary on the findings. 'When used appropriately, ADHD medications help patients not just feel better, but live safer, more productive lives,' said Dr. Sultan. He noted that this growing body of evidence underscores how effective ADHD treatment yields real-world benefits beyond symptom relief.
As the population of individuals treated for ADHD has risen, the study found that the medication's effect on reducing adverse events was less for the newly diagnosed than the previously diagnosed. In Sweden, ADHD medication use roughly tripled among youth and rose more than fivefold among adults from 2006 to 2020. During this period, the medication's impact on outcomes like injuries and crime, while still significant, became less pronounced. 'As we diagnose and treat more people with ADHD - including adults and women with milder symptoms - it's expected that the average drop in severe outcomes like arrests or accidents will be smaller,' Dr. Sultan explained. 'That doesn't mean the medication is less effective for individuals; it just means we're now helping a broader group, including those with less severe versions of ADHD. It underscores the importance of careful diagnosis and tailored treatment for each patient.'
Mental health professionals today recognize that many adults, including women, who would have been overlooked in the past now benefit from ADHD treatment. This broader inclusion is positive, as reductions in adverse outcomes such as self-harm, accidents, and criminal behavior are only part of the benefits of ADHD treatment. Dr. Sultan emphasized that the primary goal of ADHD treatment is to improve patients' daily functioning and quality of life, outcomes that are not always captured by statistics like accident or arrest rates. The new findings highlight the need to regularly re-evaluate prescribing practices and guidelines as the patient population evolves.
Both the Swedish study and Dr. Sultan's commentary are slated for publication in JAMA Psychiatry.
About
Integrative Psych is a Manhattan-based mental health practice and research clinic led by Dr. Ryan Sultan, MD, who is an Assistant Professor of Clinical Psychiatry at Columbia University Irving Medical Center and the New York State Psychiatric Institute. Integrative Psych provides a holistic, evidence-based approach to ADHD and other psychiatric conditions, combining psychopharmacology, cognitive-behavioral therapy, ketamine-assisted treatment, mindfulness, and personalized care to improve everyday functioning and well-being. Dr. Sultan's team is dedicated to advancing outcomes through both clinical innovation and real-world effectiveness research.
About Ryan S. Sultan, MD
Ryan S. Sultan, MD, Director of Integrative Psychiatry, an Assistant Professor of Clinical Psychiatry at Columbia University Irving Medical Center and a Research Scientist at the New York State Psychiatric Institute. An internationally recognized expert in ADHD, he specializes in the diagnosis and treatment of ADHD across the lifespan and focuses his research on ADHD medication outcomes and public health.
Social Links
Instagram | Facebook | YouTube | LinkedIn
Media Contact
Full Name: Yiting Huang
Title: Research Coordinator
Company Name: Integrative Psych
Email: [email protected]
Phone Number: +1(551) 263-8239
Website: https://www.integrative-psych.org/experts
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
BNP Paribas Exane Upgrades Novo Nordisk (NVO) to Neutral from Underperform
Novo Nordisk A/S (NYSE:NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from Underperform with a $54 price target. An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. The firm told investors that it sees a more balanced risk/reward now that the company's 'reality' is better reflected in the shares. Novo Nordisk A/S (NYSE:NVO) announced results for the January 1 to June 30 period on August 6, reporting an operating profit growth of 25% in Danish kroner and 29% at constant exchange rates (CER) to DKK 72.2 billion. Management also stated that sales in US Operations rose by 16% in Danish kroner (17% at CER), while sales in International Operations grew by 16% in Danish kroner (19% at CER). Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Boston Globe
2 hours ago
- Boston Globe
In 2023, Mass. hospitals pushed executive pay to new heights
That total reflected base salary, bonus pay, retirement benefits, and more. It was a 40.1 percent increase from the prior year, and included roughly $4.3 million in bonus and incentive pay. The amount is the highest total compensation reported by a Massachusetts hospital CEO in at least the last decade. In a statement, MGB Board Chairman Scott Sperling stood by Klibanski's compensation package, which he said was based on industry benchmarks with input from a consultant. Advertisement 'The challenges facing our industry are many, and the competition for top talent is unprecedented. It is imperative that we actively and robustly recruit and retain at every level to ensure we can expertly care for patients and communities for years to come,' Sperling said. 'Our objective, on average, is to base compensation for our senior executives at the 50th percentile of the current market, with performance driving any adjustments,' he said. Advertisement Previously, the health system has pointed to the leaders at other national health systems than her Massachusetts colleagues. Indeed, her 2023 salary ranked below some, including CEO of New York-based Northwell Health ($9 million) and Arizona-based Banner Health ($14 million). However Klibanski eclipsed others, including the CEOs at Cleveland Clinic ($7 million), and Mayo Clinic ($4.3 million). While the most recent compensation report lags by two years, Sperling pointed to how Klibanski had handled recent challenges as an example of what he said was her 'clear-eyed leadership,' including disruptive federal actions that have threatened research and an inpatient capacity crises. Dr. Anne Klibanski, with then-Governor Charlie Baker, pictured speaking at a coronavirus briefing in 2020. Sam Doran/Pool 'The Board of Directors fully supports Dr. Klibanski's compensation package ... which reflects her achievements and stewardship of an organization of this size and complexity,' Sperling said. Klibanski had plenty of company in the ranks of well-paid Massachusetts hospital executives in 2023. Dr. Kevin Tabb, who heads the state's second largest health system, Beth Israel Lahey Health, also reported a sizable increase, with his $5.4 million in total compensation representing a 93 percent increase from the prior year. The increases were a return to compensation Tabb reported in 2021, and were largely thanks to increases in bonus and incentive comp, as well as retirement and other deferred compensation. Dr. Eric Dickson, chief executive of UMass Memorial Health, reported a nearly 26 percent increase in total comp, to $3.9 million. The hospital said it changed its retirement plan in 2023, prompting an early payout of some benefits. That shift subsequently boosted the incentive compensation of several executives, including Dickson. Advertisement Similarly, Dr. Michael Gustafson, who left as president of UMass's flagship hospital, UMass Memorial Medical Center, in July 2023, reported a 60 percent increase in total comp to $2.8 million. Michael Dandorph, who helms Tufts Medicine, also reported a double digit increase in total comp. His $2.1 million total compensation was 32 percent higher than the previous year. Dr. Alastair Bell, CEO of Boston Medical Center Health System since June 2023 and its president since November 2022, saw his total comp increase by 34 percent to $1.9 million. Large jumps weren't universal. Other executives saw smaller changes including Dr. Kevin Churchwell ($3.2 million, down 5 percent) at Boston Children's Hospital, Dr. Mark Keroack ($2.8 million, a 4.8 percent increase) at Baystate Health where he served until 2024, and Dr. Laurie Glimcher ($2.5 million, up 5 percent) at Dana-Farber Cancer Institute which she led until 2024. Dr. Kevin Churchwell, CEO of Boston Children's Hospital, saw his compensation go down 5 percent from 2022 to 2023. Erin Clark/Globe Staff The data tracks with a study by the Harvard School of Public Health, which showed that executives overseeing large teaching hospitals nationally were the highest compensated. The study, However, there was no association between compensation and the degree of community benefit a hospital provided, nor was higher compensation associated with better patient mortality rates or readmission rates, according to the study. The Massachusetts Nurses Association lambasted executives for the pay, particularly as they said the quality of care at hospitals across the state has suffered. 'At a time when nearly 80% of Massachusetts nurses say hospital care has gotten worse in the last two years, it is deeply troubling that hospital CEOs are taking home enormous compensation packages while continuing to fail to ensure safe conditions for patients and direct care providers,' the nurses union said in a statement. Advertisement 'The very same executives receiving millions of dollars per year are making decisions not to invest in bedside care or listen to caregivers,' it said. The salaries reflect a time when hospitals were just beginning to climb out of the effects from the pandemic. Volume and revenue had begun to rebound in the year that for many hospitals ended September 2023, with Often, hospital executive compensation has been tied to a system's size and comparisons to others in the market, said Susan Malanowski, managing director of compensation consultant the Wilson Group. There are pressures on boards to hire competent executives, and the pool of applicants is smaller than it has been in the past. 'To be competitive, it is what it is,' Malanowski said. 'There is not really a big supply of competent CEOs or c-suite (executives).' While the most recent compensation data is for 2023, hospitals will be harder pressed to support large pay packages in 2025 and onward, Malanowski predicted. Uncertainty at the federal level will mean non-profit institutions will have to be more circumspect about where they set base salaries, and compensation increases are projected to be smaller. Advertisement Jessica Bartlett can be reached at
Yahoo
2 hours ago
- Yahoo
Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast
Listen here on your chosen podcast platform. Cats develop dementia similarly to humans with Alzheimer's disease. Scientists hope their findings lead to new treatments for both humans and our feline friends. For more, we spoke to the lead author, Dr Robert McGeachan, at the University of Edinburgh's Royal School of Veterinary Studies. A swarm of jellyfish forced the shutdown of France's largest nuclear power plant, Gravelines. But how unusual is this event? And, Reddit blocks the Internet Archive's Wayback Machine from archiving large portions of its site. Also in this episode: -How blowing through a conch shell could alleviate the symptoms of obstructive sleep apnoea -Lola Young urges Keir Starmer to block Rosebank oil and gas development projects -Natalie the Nerd builds a transparent GameBoy Colour
